Viridian Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Viridian Therapeutics has a total shareholder equity of $582.5M and total debt of $20.3M, which brings its debt-to-equity ratio to 3.5%. Its total assets and total liabilities are $630.4M and $47.9M respectively.
Key information
3.5%
Debt to equity ratio
US$20.33m
Debt
Interest coverage ratio | n/a |
Cash | US$613.19m |
Equity | US$582.53m |
Total liabilities | US$47.85m |
Total assets | US$630.38m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 1S1's short term assets ($626.8M) exceed its short term liabilities ($26.1M).
Long Term Liabilities: 1S1's short term assets ($626.8M) exceed its long term liabilities ($21.7M).
Debt to Equity History and Analysis
Debt Level: 1S1 has more cash than its total debt.
Reducing Debt: 1S1's debt to equity ratio has reduced from 25.4% to 3.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1S1 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 1S1 has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 37.1% each year.